Brief: CytomX Therapeutics Q2 Revenue USD 18.658 Million Vs. IBES Estimate USD 14.8 Million

CytomX Therapeutics

07/08/2025 21:10

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * CytomX Q2 2025 revenue of $18.7 mln beats analyst expectations, per LSEG data
    * Operating expenses decreased due to reduced R&D costs and program de-prioritization
    * Completed $100 mln stock offering, raising cash position to $158.1 mln
    * Announced positive interim data for CX-2051 in advanced colorectal cancer

    
    Outlook
  
    * Company expects CX-2051 Phase 1 data update by Q1 2026
    * CytomX plans CX-2051 Phase 2 study initiation in 1H 2026
    * Company anticipates CX-801 combination therapy data in 2026
    * CytomX sees cash runway extending to Q2 2027

    
    Result Drivers
  
    * POSITIVE CLINICAL DATA - Positive interim data from CX-2051 Phase 1 study in advanced colorectal cancer announced
    * DOSE EXPANSIONS - Initiated dose expansions for CX-2051 at multiple dosage levels
    * FINANCIAL STRENGTH - Completed $100 mln stock offering, enhancing cash position to support R&D

    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q2        Beat      $18.66    $14.80
 Revenue             mln       mln (5
                               Analysts
                               )
 Q2 Net              -$154,00   
 Income              0         
 Q2 Cash             $158.10    
 &                   mln       
 Investme                      
 nts                           
 Q2                  $19.94     
 Operatin            mln       
 g                             
 Expenses                      
 Q2                  -$1.29     
 Operatin            mln       
 g Income                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the biotechnology & medical research peer group is "buy"
    * Wall Street's median 12-month price target for CytomX Therapeutics Inc is $5.50, about 60.5% above its August 6 closing price of $2.17

    Press Release:  ID:nGNX86qx8K 

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)